Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT03388749 | Completed Phase 1 DMC

• 1 other identifier: MB-105
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 5

Brief Summary

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after induction therapy

Conditions

Leukemia, Myeloid, Acute

Outcome Measures

Primary Outcomes (1)

• Evaluation of safety and identification of the MTD/RP2D for L-Annamycin

  The number of patients who experience dose-limiting toxicities (DLT) will be captured at each dose level of L-Annamycin in order to determine the MTD/RP2D

  Day 1 through Day 28

Secondary Outcomes (2)

• Pharmacokinetics - Area under the plasma concentration

  Day 1 and Day 3

• Anti-leukemic activity

  Between Day 15 and Day 35 (+/- 3 days)

Study Arms (1)

Liposomal annamycin

EXPERIMENTAL

Drug: Liposomal Annamycin

Interventions

Liposomal Annamycin DRUG

2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).

Liposomal annamycin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects have a pathologically confirmed diagnosis of AML by World Health Organization classification.
• Subjects have AML that is refractory to or relapsed after induction therapy (i.e., subjects relapsed after experiencing a CR with their prior therapy). To be defined as relapse, there must be \>5% blasts in the bone marrow.
• Subjects are age ≥18 years at the time of signing informed consent.
• Subjects have not received chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and/or have recovered from the toxic side effects of any previous therapy, unless treatment is indicated as a result of progressive disease, such as hydroxyurea.
• Subjects have not received investigational therapy within 4 weeks of the first dose of study drug.
• Subjects have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
• Subjects have adequate laboratory results including the following:
• Bilirubin ≤2 times the upper limit of normal unless due to Gilbert Syndrome or leukemic infiltration of the liver
• Alanine aminotransferase (serum glutamic pyruvic transaminase), aspartate aminotransferase (serum glutamic-oxaloacetic transaminase), and alkaline phosphatase \<2.5 times the upper limit of normal unless due to organ involvement.
• Adequate renal function with creatinine levels ≤2 times the upper limit of normal.
• Subjects can understand and sign the informed consent document, can communicate with the Investigator, and can understand and comply with the requirements of the protocol.
• Women of childbearing potential must have a negative serum or urine pregnancy test.
• All men and women must agree to practice effective contraception during the entire study period and after discontinuing study drug, unless documentation of infertility exists.
• Sexually active, fertile women must use 2 effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least 6 months after discontinuing study drug.
• Sexually active men and their sexual partners must use effective contraceptive methods from the time of subject informed consent and until at least 3 months after discontinuing study drug.

You may not qualify if:

• Subjects have been diagnosed with acute promyelocytic leukemia.
• The subjects are receiving concomitant therapy that includes other chemotherapy that is or may be active against AML, except agents such as hydroxyurea, used to control the WBC count until chemotherapy, up to Day 1 of L-Annamycin administration.
• Subjects have any condition that, in the opinion of the Investigator, places the subject at unacceptable risk if they were to participate in the study.
• Subjects have central nervous system involvement.
• Subjects have left ventricular ejection fraction (LVEF) \<50%, valvular heart disease, or severe hypertension. Cardiac subjects with a New York Heart Association classification of 3 or 4 will be excluded. (Cardiology consultation should be requested if any question arises about cardiac function.) This also includes subjects with baseline QT/QTc interval \>480 msec, subjects with a history of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), and subjects who use concomitant medications that significantly prolong the QT/QTc interval.
• Subjects have clinically relevant serious comorbid medical conditions including, but not limited to, active infection, recent (less than or equal to 6 months) myocardial infarction, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, known positive status for human immunodeficiency virus and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements.
• Subjects are pregnant, lactating, or not using adequate contraception.
• Subjects have a known allergy to anthracyclines.
• Subjects have ongoing Grade 1 mucositis at the time of entry.
• Subjects are required to use moderate or strong inhibitors and inducers of Cytochrome P450 family of enzymes (CYP) and transporters that cannot be held for 3 days prior to Day 1 and during treatment days.

Sponsors & Collaborators

• Moleculin Biotech, Inc.: lead

Study Sites (5)

Medical University of Lodz

Lodz, 93-510, Poland

Location

Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego

Poznan, Poland

Location

Samodzielny Publiczny Szpital Kliniczny nr 1 im. Prof. Tadeusza Sokołowskiego w Szczecinie, Klinika Hematologii z Oddziałem Transplantacji Szpiku

Szczecin, 71-252, Poland

Location

Instytut Hematologii i Transfuzjologii, Klinika Hematologii

Warsaw, 02-776, Poland

Location

Samodzielny Szpital Kliniczny nr 1

Wroclaw, 50-367, Poland

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Robert Shepard, MD

  Moleculin Biotech, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 25, 2017
• First Posted: January 3, 2018
• Study Start: December 17, 2018
• Primary Completion: February 8, 2022
• Study Completion: February 14, 2022
• Last Updated: January 20, 2023

Record last verified: 2023-01

Locations

PL (5)